📊 RZLT Key Takeaways
Is Rezolute, Inc. (RZLT) a Good Investment?
Rezolute is a pre-revenue pharmaceutical company with an unsustainable cash burn of $37.8M annually against only $11.9M in liquid assets, creating a critical 3-4 month operational runway. The complete absence of revenue combined with negative free cash flow of -$37.9M and no clear path to profitability indicates severe fundamental weakness and near-certain need for dilutive financing.
Why Buy Rezolute, Inc. Stock? RZLT Key Strengths
- Strong balance sheet with minimal leverage (Debt/Equity: 0.11x) and low absolute liabilities of $10.6M
- Excellent liquidity position (Current Ratio: 14.18x) providing ability to meet near-term obligations
- Improving loss trajectory with EPS improving 26.3% YoY, suggesting operational efficiency gains despite negative profitability
RZLT Stock Risks: Rezolute, Inc. Investment Risks
- No revenue generation - company is pre-commercialization or failing to achieve market adoption in pharmaceutical market
- Critical cash runway of approximately 3-4 months at current burn rate with $11.9M cash against $37.8M annual operating losses
- Negative free cash flow of -$37.9M with no demonstrated path to positive operating cash flow or revenue generation
- High execution risk inherent to pharmaceutical development with uncertain clinical trial outcomes and regulatory approval timelines
- Imminent equity dilution through financing required to continue operations beyond current cash reserves
Key Metrics to Watch
- Quarterly revenue realization and commercial traction in target markets
- Monthly cash burn rate trend and updated cash position forecasts
- Operating cash flow inflection point and timing of clinical/regulatory milestones
- Insider transaction activity patterns indicating management confidence in value
Rezolute, Inc. (RZLT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.18x current ratio provides a solid financial cushion.
RZLT Profit Margin, ROE & Profitability Analysis
RZLT vs Healthcare Sector: How Rezolute, Inc. Compares
How Rezolute, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rezolute, Inc. Stock Overvalued? RZLT Valuation Analysis 2026
Based on fundamental analysis, Rezolute, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rezolute, Inc. Balance Sheet: RZLT Debt, Cash & Liquidity
RZLT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rezolute, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.33 indicates the company is currently unprofitable.
RZLT Revenue Growth, EPS Growth & YoY Performance
Rezolute, Inc. Dividends, Buybacks & Capital Allocation
RZLT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rezolute, Inc. (CIK: 0001509261)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RZLT
What is the AI rating for RZLT?
Rezolute, Inc. (RZLT) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RZLT's key strengths?
Claude: Strong balance sheet with minimal leverage (Debt/Equity: 0.11x) and low absolute liabilities of $10.6M. Excellent liquidity position (Current Ratio: 14.18x) providing ability to meet near-term obligations.
What are the risks of investing in RZLT?
Claude: No revenue generation - company is pre-commercialization or failing to achieve market adoption in pharmaceutical market. Critical cash runway of approximately 3-4 months at current burn rate with $11.9M cash against $37.8M annual operating losses.
What is RZLT's revenue and growth?
Rezolute, Inc. reported revenue of N/A.
Does RZLT pay dividends?
Rezolute, Inc. does not currently pay dividends.
Where can I find RZLT SEC filings?
Official SEC filings for Rezolute, Inc. (CIK: 0001509261) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RZLT's EPS?
Rezolute, Inc. has a diluted EPS of $-0.40.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RZLT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Rezolute, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RZLT stock overvalued or undervalued?
Valuation metrics for RZLT: ROE of -32.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RZLT stock in 2026?
Our dual AI analysis gives Rezolute, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RZLT's free cash flow?
Rezolute, Inc.'s operating cash flow is $-37.8M, with capital expenditures of $153.0K.
How does RZLT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -32.0% (avg: 15%), current ratio 14.18 (avg: 2).